Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. - Wikidata - awgldk - TriplyDB

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

http://www.wikidata.org/entity/Q34247562

about

The influence of gender on the effects of aspirin in preventing myocardial infarction Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin Heparin versus placebo for non-ST elevation acute coronary syndromes Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era Heparin versus placebo for acute coronary syndromes Caerphilly and Speedwell collaborative heart disease studies. The Caerphilly and Speedwell Collaborative Group The first randomized trial of aspirin for heart attack and the advent of systematic overviews of trials Debate: When should we intervene in unstable angina - Time for an old look?Arterial indications for the low molecular weight heparins Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era Ticagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agent Risks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic Review The Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review Article Antiplatelet therapy in cardiovascular disease Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes Errors of omission in the treatment of prehospital chest pain patients Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics?Unstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapy Preventing atherosclerotic events with aspirin Clinical evidence of dose-dependent interaction between aspirin and angiotensin-converting enzyme inhibitors Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy Salicylate-induced degeneration of cochlea spiral ganglion neurons-apoptosis signaling Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Influence of aspirin on pilocarpine-induced epilepsy in mice.Acute coronary syndromes: diagnosis and management, part I Preventive Aspirin and Other Antiplatelet Medication Use Among U.S. Adults Aged ≥ 40 Years: Data from the National Health and Nutrition Examination Survey, 2011-2012.Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.Interaction of ACE inhibitors and aspirin in patients with congestive heart failure.Antiplatelet therapy--Part I Predictors of risk in patients with unstable angina admitted to a district general hospital.Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction.

P2860

Q21245274-82B00FCF-C082-4752-A769-C80B0F8D2FE2 Q22306342-92A73BBD-C01E-4F63-B7B3-36B1AF4AB321 Q24193744-82A3A6ED-C279-4EB8-896E-7095227D354D Q24236794-E4BC6FF8-D152-47EE-954E-6419F24C4DD3 Q24243000-FB96E950-40F1-454D-A3F6-5B57F2E37833 Q24518764-B66F0DB9-0CD1-4113-9355-6791205E21E5 Q24675893-189D887B-012C-448E-B898-7AA77C65BA12 Q24792342-590DAFBA-F6AC-40FA-ACE1-2A6A6C20961D Q24806932-23252460-0FFC-41C1-98BC-B6CC64406306 Q26471900-1C304976-EA60-4E17-8185-B7C811FADD56 Q26829967-D8466D04-0DA7-4D9F-9434-36B07BCF058F Q27026079-7870C642-69F4-41D5-8618-D7318D09E8CE Q28075382-906B8A3B-E5EA-4981-BFE9-8993717AB8AA Q28167737-48A08A01-363B-467D-8F48-E89E4FD8B302 Q28174646-44530C87-06AA-4B8F-B760-A1F83C5E9D55 Q28177271-7EA4C2EF-BC20-43C5-9384-B2F6840ACA8F Q28184770-3BC9002D-6147-4F5E-AF8B-AE5CFBAFDD66 Q28191395-BDC30186-EB3A-483C-A705-DBD13CB9731A Q28192025-F762222A-06FC-4086-ABD9-248DC922FB26 Q28192083-D2552808-75CE-4EE2-A2AD-CCABDF10EDE3 Q28193095-38912536-382C-48AD-9427-8B8A74E976FD Q28193220-E5FA1765-79D1-40A3-AA7F-EEE459DDBBAA Q28200757-9C70BDE9-59E1-4761-965D-64D570E20773 Q28211998-CF793E20-931A-4F08-A51E-AE4373BAB830 Q28220382-344772E2-2CAB-4607-862F-E7E7AE1EA0D9 Q28395683-FEAADD7F-6919-485A-B974-EFD133FC4C22 Q28396990-EF1DC545-D8AC-4CDC-8206-36DE576DBE3E Q29619529-7D315EFC-3EA1-4077-AA88-6E82B8111C6C Q30234909-4D2E1687-82A0-4BE5-B600-B50C79051B18 Q30438893-DEF0196E-27C5-425E-9515-449B203BBB99 Q30457930-2CFCD955-A73A-4999-87CD-CE700DA63868 Q30490718-37EBFA39-8619-43EE-97CA-EC0948F08118 Q31021374-B5C76560-8649-4143-934D-DC084D595A8C Q33381356-6D40752C-0BEC-4673-AF7A-F1BB355CC4A7 Q33554381-B0AEE977-A135-4467-9CBC-14BA2BE813EF Q33590391-6303EC10-A915-4AE1-B2F3-8199956E79A6 Q33592464-2D719778-B34A-4A3C-A346-20693F979BCC Q33606832-B70FAFE0-E41E-461E-AC0E-B35BCD6E3B45 Q33611971-05FBE64F-8F32-4CE8-A08B-284414987F3B Q33612840-9F3E6E3B-10AC-4184-9D00-DD1162252C89

P2860

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

http://www.wikidata.org/entity/Q34247562

description

1983 nî lūn-bûn

@nan

1983 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1983 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1983年の論文

@ja

1983年論文

@yue

1983年論文

@zh-hant

1983年論文

@zh-hk

1983年論文

@zh-mo

1983年論文

@zh-tw

1983年论文

@wuu

name

Protective effects of aspirin ...... inistration Cooperative Study.

@ast

Protective effects of aspirin ...... inistration Cooperative Study.

@en

Protective effects of aspirin ...... inistration Cooperative Study.

@nl

type

label

Protective effects of aspirin ...... inistration Cooperative Study.

@ast

Protective effects of aspirin ...... inistration Cooperative Study.

@en

Protective effects of aspirin ...... inistration Cooperative Study.

@nl

prefLabel

Protective effects of aspirin ...... inistration Cooperative Study.

@ast

Protective effects of aspirin ...... inistration Cooperative Study.

@en

Protective effects of aspirin ...... inistration Cooperative Study.

@nl

P1433

Q34247562-7E7C90B4-74E2-4D13-A21D-A1DF2671267A

P1476

Q34247562-6794CA7D-E123-4B00-850A-5796D98ABCAE

P2093

Q34247562-0D685CBD-C414-43B9-AA54-55D1D92DCB40

Q34247562-32AF1656-AD50-4D84-87A6-E21CA0B7ACF9

Q34247562-35589B20-0B6B-4252-9784-1D29B1C3CA92

Q34247562-67517BE4-AA4A-4B40-840B-280783477433

Q34247562-70C4405C-69D5-4BF8-AC7A-9AADCBBF7308

Q34247562-85160AAA-380E-4628-8B49-8ABC8398A3FC

Q34247562-8A670CFE-5161-42EE-A685-BFB01B28E531

Q34247562-C3FC1694-4B83-4CC2-B443-628E702D6722

Q34247562-CB2C9AA4-5764-404C-A912-5012F836B06D

Q34247562-E07852DB-5925-4A07-A5C8-0CF9E697F81B

P304

Q34247562-5368FDFC-78C3-47DA-8F51-A6106D3B93A8

P31

Q34247562-CE9B0A95-F463-49E0-86AB-61B5AF03C9E6

P356

Q34247562-D4D61828-3DDA-4A81-8B85-5143052EDE10

P407

Q34247562-E69125F8-2C3E-4550-AFBB-430403CDAAA6

P433

Q34247562-D51BB7FC-ED48-44D4-A8B7-1514761865B3

P478

Q34247562-E4159BCF-1A59-4949-940C-0391D45D911A

P577

Q34247562-5C533226-E23C-4AD2-9D93-86A57116D83C

P698

Q34247562-CF2F8A2E-4D10-46D6-B079-30C6C95E3E22

P921

Q34247562-2B21F6BF-36BF-48FC-9065-E49CC3B64658

Q34247562-4DD1990B-29F1-42F6-8CB1-F0DAFA95BCD1

Q34247562-7E8104CF-A4D9-4AC4-8F93-E8A8314F2CCE

P356

NEJM198308183090703

P1433

The New England Journal of Medicine

P1476

Protective effects of aspirin ...... inistration Cooperative Study.

@en

P2093

D G Archibald

http://www.w3.org/2001/XMLSchema#string

E Chesler

http://www.w3.org/2001/XMLSchema#string

E Linares

http://www.w3.org/2001/XMLSchema#string

H D Lewis

http://www.w3.org/2001/XMLSchema#string

H DeMots

http://www.w3.org/2001/XMLSchema#string

H W Schnaper

http://www.w3.org/2001/XMLSchema#string

J E Doherty

http://www.w3.org/2001/XMLSchema#string

J M Pouget

http://www.w3.org/2001/XMLSchema#string

J W Davis

http://www.w3.org/2001/XMLSchema#string

M M LeWinter

http://www.w3.org/2001/XMLSchema#string

P304

396-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJM198308183090703

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

309

http://www.w3.org/2001/XMLSchema#string

P577

1983-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

6135989

http://www.w3.org/2001/XMLSchema#string

P921